Medical Toxicology and Adverse Drug Experience

, Volume 4, Issue 6, pp 452–467 | Cite as

Drug-Induced Ototoxicity

Pathogenesis and Prevention
  • May Y. Huang
  • Jochen Schacht
Adverse Drug Experience Review

Summary

Ototoxicity is a disabling adverse effect of several widely used classes of drugs, such as diuretics, anti-inflammatory agents, antineoplastic agents and aminoglycoside antibiotics.

High-dose therapy with either diuretics or anti-inflammatory agents is primarily associated with acute and transient impairment of hearing or tinnitus. In contrast, long term treatment with antineoplastic agents or aminoglycoside antibiotics is typically associated with delayed and irreversible loss of hearing; lesions in the organ of Corti include the destruction of auditory sensory cells. Vestibular function can also be compromised by ototoxic drugs.

Occasional cases of ototoxicity have been reported for a variety of other therapeutic compounds and environmental toxins. In addition, the simultaneous administration of multiple agents which are potentially ototoxic can lead to Synergistic loss of hearing. Exposure to loud noise may also potentiate the hearing loss due to cochleotoxic drugs.

Ototoxic agents can impair the sensory processing of sound at many cellular or subcellular sites. However, the molecular mechanisms of ototoxicity have not been established for most of these drugs, and structure-toxicity relationships have not been determined. It has therefore been difficult to predict the ototoxic potential of new drugs, and rational approaches to the prevention of ototoxicity are still lacking. The clinical and experimental features of ototoxicity are reviewed for several classes of drugs, with an emphasis on current knowledge of the mechanism and the possibilities for the prevention of ototoxicity for each.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aggarwal SK, Niroomand-Rad I. Effect of cisplatin on the plasma membrane phosphatase activities in ascites sarcoma-180 cells: a cytochemical study. Journal of Histochemistry and Cytochemistry 31: 307–317, 1983PubMedGoogle Scholar
  2. Anniko M, Sobin A. Cis-platin: evaluation of its ototoxic potential. American Journal of Otolaryngology 7: 276–293, 1986PubMedGoogle Scholar
  3. Anniko M, Takada A, Schacht J. Comparative ototoxicities of gentamicin and netilmicin in three model systems. American Journal of Otolaryngology 3: 422–433, 1982PubMedGoogle Scholar
  4. Aran JM, Cazals Y, Erre JP, Guilhaume A. Conflicting electrophysiological and anatomical data from drug impaired guinea pig cochleas. Acta Otolaryngologica 87: 300–309, 1979Google Scholar
  5. Aran JM, Erre JP, Guilhaume A, Aurousseau C. The comparative ototoxicities of gentamicin, tobramycin and dibekacin in the guinea pig. Acta Otolaryngologica 390 (Suppl.): 3–30, 1982Google Scholar
  6. Aronoff GR, Pottratz ST, Brier ME, et al. Aminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrobial Agents and Chemotherapeutics 23: 74–78, 1983Google Scholar
  7. Aursnes J. Vestibular damage from chlorhexidine in guinea pigs. Acta Oto-Laryngologica 92: 89–100, 1981PubMedGoogle Scholar
  8. Aursnes J. Ototoxic effect of iodine disinfectants. Acta Otolaryngologica 93: 219–226, 1982Google Scholar
  9. Axelsson A. Comparative anatomy and development of cochlear blood vessels. Association for Research and Otolaryngology 11th Midwinter Meeting, Clearwater Beach, Florida, January 31–February 4, 1988. Abstract no. 81, p. 68, 1988Google Scholar
  10. Bagger-Sjöbäck D, Filipek CS, Schacht J. Characteristics and drug responses of cochlear and vestibular adenylate cyclase. Archives of Otorhinolaryngology 228: 217–222, 1980Google Scholar
  11. Ballantyne JC. Ototoxicity: a clinical review. Audiology 12: 325–336, 1973PubMedGoogle Scholar
  12. Baranak CC, Wetmore RF, Packer RJ. Cis-platinum ototoxicity after radiation treatment: an animal model. Journal of Neuro-Oncology 6: 261–267, 1988PubMedGoogle Scholar
  13. Belliveau JF, Posner MR, Ferrari L, et al. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treatment Reports 70: 1215–1217, 1986PubMedGoogle Scholar
  14. Belt RJ, Himmelstein KJ, Patton TF, et al. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiamine platinum (II). Cancer Treatment Reports 63: 1515–1521, 1979PubMedGoogle Scholar
  15. Bennett WM, Elliott WC, Houghton DC, et al. Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading. Antimicrobial Agents and Chemotherapy 22: 508–512, 1982PubMedGoogle Scholar
  16. Bosher SK. The nature of the ototoxic actions of ethacrynic acid upon the mammalian endolymph system. I. Functional aspects. Acta Otolaryngologica 89: 407–418, 1980Google Scholar
  17. Brier ME, Mayer PR, Brier RA, et al. Relationship between rat renal accumulation of gentamicin, tobramycin, and netilmicin and their nehrotoxicities. Antimicrobial Agents and Chemotherapy 27: 812–816, 1985PubMedGoogle Scholar
  18. Brion N, Barge J, Godefray I, et al. Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits. Antimicrobial Agents and Chemotherapy 25: 168–172, 1984PubMedGoogle Scholar
  19. Brock P, Pritchard J, Bellman S, Pinkerton CR. Ototoxicity of high-dose cis-platinum in children. Medical and Pediatric Oncology 16: 368–369, 1988PubMedGoogle Scholar
  20. Brown RD. Comparison of the cochlear toxicity of sodium ethacrynate, furosemide, and the cysteine adduct of sodium ethacrynate in cats. Toxicology and Applied Pharmacology 31: 270–282, 1975PubMedGoogle Scholar
  21. Brown RD, McElwee Jr TT. Effects of intra-arterially and intravenously administered ethacrynic acid and furosemide on cochlear NI in cats. Toxicology and Applied Pharmacology 22: 589–594, 1972PubMedGoogle Scholar
  22. Brummett RE, Fox KE. Studies of aminoglycoside ototoxicity in animal models. In Whelton & Neu (Eds) The aminoglycosides. Microbiology, clinical use and toxicology, pp. 419–451, Dekker, New York, 1982Google Scholar
  23. Brummett RE, Harris RF, Lindgren JA. Detection of ototoxicity from drugs applied topically to the middle ear space. Laryngoscope 86: 1177–1187, 1976PubMedGoogle Scholar
  24. Brummett RE, Morrison R, Matthews J. Possible site of action of erythromycin ototoxicity in the human. Association for Research in Otolaryngology 12th Midwinter Meeting, St Petersburg Beach, Florida, February 5–9, 1989. Abstract no. 220, p. 185, 1989Google Scholar
  25. Brummett RE, Traynor J, Brown R, Himes DL. Cochlear damage resulting from kanamycin and furosemide. Acta Oto-Laryngologica 80: 86–92, 1975PubMedGoogle Scholar
  26. Burg M, Green N. Effects of ethacrynic acid on the thick ascending limb of Henle’s loop. Kidney International 4: 301–308, 1973PubMedGoogle Scholar
  27. Carlstedt BC, Uaamnuichai M, Day RB, et al. Aminoglycoside dosing in pediatric patients. Therapeutic Drug Monitoring 11: 38–43, 1989PubMedGoogle Scholar
  28. Cazals Y, Li XQ, Aurousseau C, Didier A. Acute effects of noradrenalin related vasoactive agents on the ototoxicity of aspirin: an experimental study in the guinea pig. Hearing Research 36: 89–96, 1988PubMedGoogle Scholar
  29. Comis SD, Rhys-Evans PH, Osborne MP, et al. Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. Journal of Laryngology and Otology 100: 1375–1383, 1986PubMedGoogle Scholar
  30. Cooperman LB, Rubin IL. Toxicity of ethacrynic acid and furosemide. American Heart Journal 85: 831–834, 1973PubMedGoogle Scholar
  31. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. Journal of Antimicrobial Chemotherapy 23: 441–451, 1989PubMedGoogle Scholar
  32. Cramer R. Erythromycin ototoxicity. Drug Intelligence and Clinical Pharmacy 20: 764–765, 1986Google Scholar
  33. Cummings and Harker et al. (Eds). Otolaryngology —head and neck surgery, Vol. IV, pp. 2956–3156, CV Mosby Company, St Louis, 1986Google Scholar
  34. Cutler RE, Blair AD. Clinical pharmacokinetics of frusemide. Clinical Pharmacokinetics 4: 279–296, 1979PubMedGoogle Scholar
  35. Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrobial Agents and Chemotherapy 8: 58–62, 1975PubMedGoogle Scholar
  36. Darrouzet J, de Lima Sobrinho E. Oreille interne, kanamycine et traumatisme acoustique, étude éxperimentale. Revue de Laryngologie Otologie Rhinologie 83: 781–806, 1962PubMedGoogle Scholar
  37. Davis RR, Brummett RE, Bendrick TW, Hirnes DL. Dissociation of maximum concentrations of kanamycin in plasma and perilymph from other ototoxic effects. Journal of Antimicrobial Chemotherapy 14: 291–302, 1984PubMedGoogle Scholar
  38. Dayal VS, Barok WG. Cochlear changes from noise, kanamycin, and aging. Laryngoscopy 85 (Suppl.): 1–18, 1975Google Scholar
  39. de Groot JCMJ, Veldman JE. Early effects of genamicin on inner ear glycocalyx cytochemistry. Hearing Research 35: 39–46, 1988PubMedGoogle Scholar
  40. Dulon D, Aran JM, Zajic G, Schacht J. Comparative uptake of gentamicin, netilmicin and amikacin in the guinea pig cochlea and vestibule. Antimicrobial Agents and Chemotherapy 30: 96–100, 1986PubMedGoogle Scholar
  41. Dulon D, Zajic G, Schacht J. Intracellular ionized calcium in single outer hair cells during stimulation in vitro. Association for Research in Otolaryngology 12th Midwinter Meeting, St Petersburg Beach, Florida, February 5–9, 1989Google Scholar
  42. Dumas M, de Gislain C, d’Athis P,et al. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum. Cancer Chemotherapy and Pharmacology 23: 37–40, 1989PubMedGoogle Scholar
  43. Engineer MS, Ho DW, Khokhar AR, et al. A comparison of the effects of cisplatin and N-methyliminodiacetato-(1,2-diaminocyclohexan)-platinum (II) on renal function and gentamicin excretion in rats. Toxicology 47: 307–315, 1987PubMedGoogle Scholar
  44. Escoubet B, Amsallem P, Ferrary E, Tran Ba Huy P. Prostaglandin synthesis by the cochlea of the guinea pig. Influence of aspirin, gentamicin and acoustic stimulation. Prostaglandins 29: 589–599, 1985PubMedGoogle Scholar
  45. Evans DA, Buring J, Mayrent S, et al. Qualitative overview of randomized trials of aminoglycosides. American Journal of Medicine 80 (Suppl. 6B): 39–43, 1986PubMedGoogle Scholar
  46. Evans EF, Kline R. The effects of intracochlear and systemic furosemide on the properties of single cochlear nerve fibers in the cat. Journal of Physiology 331: 409–427, 1982PubMedGoogle Scholar
  47. Evans EF, Wilson JP, Borerwe TA. Animal models of tinnitus. In CIBA Foundation Symposium 85, pp. 108–129, Pitman, London, 1981Google Scholar
  48. Fechter LD, Young JS, Nuttall AL. Trimethyltin ototoxicity: evidence for a cochlear site of injury. Hearing Research 23: 275–282, 1986PubMedGoogle Scholar
  49. Federspil P, Schätzle W, Tiesler E. Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. Journal of Infectious Diseases 134 (Suppl.): S200–S205, 1976PubMedGoogle Scholar
  50. Fee Jr WE. Aminoglycoside ototoxicity in the human. Laryngoscope 90 (Suppl.): 1–19, 1980PubMedGoogle Scholar
  51. Fong IW, Fenton RS, Bird R. Comparative toxicity of gentamicin versus tobramycin: randomized prospective study. Journal of Antimicrobial Chemotherapy 7: 81–88, 1981PubMedGoogle Scholar
  52. Forge A. Outer hair cell loss and supporting cell expansion following chronic gentamicin treatment. Hearing Research 35: 39–46, 1985Google Scholar
  53. Forge A, Davies JP, Zajic G, et al. Gentamicin alters membrane structure: freeze-fracture studies of hair cells and liposomes. Association for Research in Otolaryngology 12th Midwinter Meeting, St Petersburg Beach, Florida, February 5–9, 1989. Abstract no. 124, p. 109, 1989aGoogle Scholar
  54. Forge A, Zajic G, Davies S, et al. Gentamicin alters membrane structure as shown by freeze-fracture of liposomes. Hearing Research 37: 129–140, 1989bPubMedGoogle Scholar
  55. Fox KE, Brummett RE. The relationship between cytotoxicity of kanamycin and ethacrynic acid for mammalian cells in vitro and their ototoxicity in vivo. Acta Otolaryngologica 87: 72–78, 1979Google Scholar
  56. Gatell JM, San Miguel JG, Zamora L, et al. Comparison of nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrobial Agents and Chemotherapy 23: 897–901, 1983PubMedGoogle Scholar
  57. Goldman WJ, Bielinski TC, Mattis PA. Cochlear microphonic potential response of the dog to diuretic compounds. Toxicology and Applied Pharmacology 25: 259–266, 1973PubMedGoogle Scholar
  58. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39: 1362, 1977Google Scholar
  59. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemotherapy and Pharmacology 18: 69–73, 1986PubMedGoogle Scholar
  60. Goycoolea MV, Muchow D, Martinez GC, et al. Permeability of the human round-window membrane to cationic ferritin. Archives of Otolaryngology —Head and Neck Surgery 114: 1247–1251, 1988PubMedGoogle Scholar
  61. Goycoolea MV, Paparella MM, Goldberg B, et al. Permeability of the middle ear to staphylococcal pyrogenic exotoxin in otitis media. International Journal of Pediatric Otorhinolaryngology 1: 301–308, 1980PubMedGoogle Scholar
  62. Green TP, Rybak LP, Mirkin BL, et al. Pharmacologic determinants of ototoxicity of furosemide in the chinchilla. Journal of Pharmacology and Experimental Therapeutics 216: 537–542, 1981PubMedGoogle Scholar
  63. Guiliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. Journal of Pharmacology and Experimental Therapeutics 236: 470–475, 1986Google Scholar
  64. Hawkins Jr JE. Drug ototoxicity. In Keidel & Neff (Eds) Handbook of sensory physiology, pp. 707–748, Springer, New York, 1976Google Scholar
  65. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372, 1977PubMedGoogle Scholar
  66. Hegedüs L, van der Vijgh WJF, Kelin I, et al. Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chemotherapy and Pharmacology 20: 211–212, 1987PubMedGoogle Scholar
  67. Helson L, Okonkwo E, Anton L, Cvitkovic E. Cisplatinum ototoxicity. Clinical Toxicology 13: 469–478, 1978PubMedGoogle Scholar
  68. Henley III CM, Schacht J. Pharmacokinetics of aminoglycoside antibiotics in blood, inner ear fluids and tissues and their relationship to ototoxicity. Audiology 27: 137–146, 1988PubMedGoogle Scholar
  69. Hinshaw HC, Feldman WH. Streptomycin in the treatment of clinical tuberculosis. Proceedings of the Mayo Clinic 20: 313–318, 1945Google Scholar
  70. Hoffman DW, Whitworth CA, Joyner-Triplett N, Rybak LP. Glutathione depletion markedly enhances drug-induced hearing loss —possible mechanism of ototoxicity. Abstracts of the Society for Neuroscience Meeting 12: 1561, 1986Google Scholar
  71. Holdener EE, Park CH, Belt RJ, et al. Effect of mannitol and plasma on the cytotoxicity of cis-platin. European Journal of Cancer and Clinical Oncology 19: 515–518, 1983Google Scholar
  72. Huang M, Schacht J. Outer hair cells as potential targets of inflammatory mediators. Annals of Otology, Rhinology, Laryngology, in press, 1989aGoogle Scholar
  73. Huang M, Schacht J. Isolated cochlear hair cells as an assay for the ototoxicity of drugs. American Academy of Otolaryngology —Head and Neck Surgery Research Forum, New Orleans, abstract, in press, 1989bGoogle Scholar
  74. Humes HD, Sastrasinh M, Weinberg JM. Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity. Journal of Clinical Investigation 73: 134–147, 1984PubMedGoogle Scholar
  75. Juhn SK, Rybak LP, Morizono T, Green TP. Pharmacokinetics of furosemide in relation to the alteration of endocochlear potential. Scandinavian Audiology 14 (Supl.): 39–49, 1981PubMedGoogle Scholar
  76. Khokhar AR, Brown DB, McCormack JJ, Hacker MP. Synthesis and antitumor activity of a series of (aminoethylpyrrolidine) platinum complexes. Cancer Chemotherapy and Pharmacology 23: 15–18, 1989PubMedGoogle Scholar
  77. Klaassen CD, Fitzgerald TJ. Metabolism and biliary excretion of ethacrynic acid. Journal of Pharmacology and Experimental Therapeutics 191: 548–556, 1974PubMedGoogle Scholar
  78. Kohn S, Fradis M, Pratt H, et al. Cisplatin ototoxicity in guinèa pigs with special reference to toxic effects in the stria vascularis. Laryngoscope 98: 865–871, 1988PubMedGoogle Scholar
  79. Komune S, Snow JB. Potentiating effects of cisplatin and ethacrynic acid in ototoxicity. Archives of Otolaryngology 107: 594–497, 1981PubMedGoogle Scholar
  80. Kopelman J, Budnick AS, Sessions RB, et al. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscopy 98: 858–864, 1988Google Scholar
  81. Kroese ABA, Das A, Hudspeth AJ. Blockade of the transduction channels of hair cells in the bullfrog’s sacculus by aminoglycoside antibiotics. Hearing Research 37: 203–218, 1989PubMedGoogle Scholar
  82. Kroese ABA, van den Bercken J. Effects of ototoxic antibiotics on sensory hair cell functioning. Hearing Research 6: 183–197, 1982PubMedGoogle Scholar
  83. Laurell G, Engström B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hearing Research 38: 27–34, 1989aPubMedGoogle Scholar
  84. Laurell G, Engström B. The combined effect of cisplatin and furosemide on hearing function in guinea pigs. Hearing Research 38: 19–26, 1989bPubMedGoogle Scholar
  85. Lazenby CM, Harper ES. Effects of neomycin on K+ transport into inside-out erythrocyte membrane vesicles. Biochemical Society Transactions 625th Meeting, London, p. 598, 1987Google Scholar
  86. Lazenby CM, Lee SJ, Harper ES, Gescher A. Glutathione depletion in the guinea pig and its effect on the acute cochlear toxicity of ethacrynic acid. Biochemical Pharmacology 37: 3743–3747, 1988PubMedGoogle Scholar
  87. Lee SM, Pattison ME, Michael UF. Nitrendipine protects against aminoglycoside nephrotoxicity in the rat. Journal of Cardiovascular Pharmacology 9 (Suppl. 1): S65–S69, 1987PubMedGoogle Scholar
  88. Lenoir M, Puel J-L. Dose-dependent changes in the rat cochlea following aminoglycoside intoxication. II. Histological study. Hearing Research 26: 199–209, 1987PubMedGoogle Scholar
  89. Lerner AM, Reyes MP, Cone LA, et al. Randomized, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1: 1123–1126, 1983PubMedGoogle Scholar
  90. Lerner SA, Matz GJ. Suggestion for monitoring patients during treatment with aminoglycoside antibiotics. Otolaryngology —Head and Neck Surgery 87: 222–228, 1979Google Scholar
  91. Levin G, Behrenth E. Irreversible ototoxic effect of erythromycin. Scandinavian Audiology 15: 41–42, 1986PubMedGoogle Scholar
  92. Lock CJL, Bradford J, Faggiani R, et al. The structure of platinum anticancer agents and their metabolites. Journal of Clinical Hematology and Oncology 7: 63–78, 1977Google Scholar
  93. Marks SC, Schacht J. Effects of ototoxic diuretics on cochlear Na+-K+-ATPase and adenylate cyclase. Scandinavian Audiology 14 (Suppl.): 131–137, 1981PubMedGoogle Scholar
  94. Marques DM, Clark CS, Hawkins Jr JE. Potentiation of cochlear injury by noise and ototoxic antibiotics in guinea pigs. Journal of the Acoustical Society of America 57 (Suppl.): S60, 1975Google Scholar
  95. Mathog RH, Klein Jr WJ. Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia. New England Journal of Medicine 280: 1223–1224, 1969PubMedGoogle Scholar
  96. Matz GJ. The ototoxic effects of ethacrynic acid in man and animals. Laryngoscope 86: 1065–1086, 1976PubMedGoogle Scholar
  97. Matz GJ, Beal DD, Krames L. Ototoxicity of ethacrynic acid demonstrated in a human temporal bone. Archives of Otolaryngology 90: 152–159, 1969PubMedGoogle Scholar
  98. McCabe PA, Dey FL. The effect of aspirin upon auditory sensitivity. Annals of Otology, Rhinology, Laryngology 74: 312–325, 1965Google Scholar
  99. McFadden D, Plattsmier HS. Aspirin can potentiate the temporary hearing loss induced by intense sounds. Hearing Research 9: 295–316, 1983PubMedGoogle Scholar
  100. McGinness JE, Procter PH, Demopoulos HB, et al. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Physiological Chemistry and Physics 10: 267–277, 1978PubMedGoogle Scholar
  101. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. Cancer 55: 41–43, 1985PubMedGoogle Scholar
  102. Melichar I, Syka J. The effects of ethacrynic acid upon the potassium concentration in guinea pig inner ear fluids. Hearing Research 1: 35–41, 1978PubMedGoogle Scholar
  103. Mitchell C, Brummett R, Himes D, Vernon J. Electrophysiological study of the effect of sodium salicylate upon the cochlea. Archives of Otolaryngology 98: 297–301, 1973PubMedGoogle Scholar
  104. Mitchell JR, Nelson WL, Potter WE, et al. Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite. Journal of Pharmacology and Experimental Therapeutics 199: 41–52, 1976PubMedGoogle Scholar
  105. Moore RD, Smith CR, Leitman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. Journal of Infectious Disease 149: 23–30, 1984bGoogle Scholar
  106. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Annals of Internal Medicine 100: 352–357, 1984aPubMedGoogle Scholar
  107. Morizono T, Paparella MM, Juhn SK. Ototoxicity of propylene glycol in experimental animals. American Journal of Otolaryngology 1: 393–399, 1980PubMedGoogle Scholar
  108. Myers EN, Bernstein JM. Salicylate ototoxicity. Archives of Otolaryngology 82: 483–493, 1965PubMedGoogle Scholar
  109. Noone P, Parsons TMC, Pattison JR, et al. Experience in monitoring gentamicin therapy treatment of serious gram-negative sepsis. British Journal of Medicine 1: 477–481, 1974Google Scholar
  110. Offner FF, Dallos P, Cheatham MA. Positive endocochlear potential: mechanism of production by marginal cells of the stria vascularis. Hearing Research 29: 117–124, 1987PubMedGoogle Scholar
  111. Ohlsen AK, Nuttall AL, Miller JM. The influence of adrenergic drugs on the cochlear blood flow. Association for Research in Otolaryngology 12th Midwinter Meeting, St Petersburg Beach, Florida, February 5–9, 1989. Abstract no. 116, p. 103, 1989Google Scholar
  112. Ohtani I, Ohtsuki K, Aikawa T, et al. Protective effect of fosfomycin against cisplatin-induced ototoxicity in rats. Ear Research Japan 15: 290–292, 1984Google Scholar
  113. Ohtani I, Ohtsuki K, Aikawa T, et al. Protective effect of fosfo-mycin against aminoglycoside ototoxicity. Otology-Rhinology-Laryngology 47: 42–48, 1985Google Scholar
  114. Ohtsuki K, Ohtani I, Aikawa T, et al. The ototoxicity and the accumulation in the inner ear of the various aminoglycoside antibiotics. Ear Research Japan 13: 85–87, 1982Google Scholar
  115. Orsulakova A, Schacht J. A biochemical mechanism of the ototoxic interaction between neomycin and ethacrynic acid. Acta Oto-laryngologica 93: 43–48, 1981Google Scholar
  116. Otto WC, Brown RD, Gage-White L, et al. Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs. Hearing Research 35: 79–86, 1988PubMedGoogle Scholar
  117. Ouchi J, Ohtani I. Studies on the otoxicity of kanamycin (the correlation between electrophysiological findings and histopathological changes). Practice Oto-Rhino-Laryngologica 31: 218–233, 1969Google Scholar
  118. Palmieri L, Cioni L, Puccini R, Schnoblinova Z. A study on reduced gentamicin nephrotoxicity and increased antibacterial action by a gentamicin-fosfomycin association in vitro and vivo. Drugs and Experimental Clinical Research 9: 537–543, 1983Google Scholar
  119. Parravicini L, Arpini A, Bamonte F, et al. Comparative ototoxicity of amikacin, gentamicin, netilmicin, and tobramycin in guinea pigs. Toxicology and Applied Pharmacology 65: 222–230, 1982PubMedGoogle Scholar
  120. Piel I, Myer D, Perlia C, Wolfe V. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemotherapy Reports 58: 871–875, 1974Google Scholar
  121. Pryor GT, Howd RA. Toluene-induced ototoxicity by subcutaneous administration. Neurobiology and Toxicology 8: 103–104, 1986Google Scholar
  122. Pryor GT, Rebert CS, Dickinson J, Feeney EM. Factors affecting toluene-induced ototoxicity in rats. Neurobiology and Toxicology 6: 223–238, 1984Google Scholar
  123. Quick CA, Hoppe W. Permanent deafness associated with furosemide administration. Annals of Otology 84: 94–101, 1975Google Scholar
  124. Quirk WS, Dengerink HA, Harding JW, et al. Autoregulation of cochlear blood flow in normotensive and spontaneously hypertensive rats following intracerebroventricularly mediated adjustment of blood pressure. Hearing Research 38: 119–124, 1989aPubMedGoogle Scholar
  125. Quirk WS, Wright JW, Coleman JK, Dengerink HA. Autoregulation of cochlear blood flow in Wistar-Kyoto rats. Association for Research in Otolaryngology 12th Midwinter Meeting, St Petersburg Beach, Florida, February 5–9, 1989. Abstract no. 115, p. 103, 1989bGoogle Scholar
  126. Rankin LJ, Krous H, Fryer AW, Whang R. Enhancement of gentamicin nephrotoxicity by magnesium depletion. Mineral and Electrolyte Metabolism 10: 199–203, 1984PubMedGoogle Scholar
  127. Rennick BR. Renal tubule transport of organic cations. American Journal of Physiology 240: F83–F89, 1981PubMedGoogle Scholar
  128. Rifkin SI, De Quesada AM, Pickering MJ, Shires Jr DL. Deafness associated with oral furosemide. Southern Medical Journal 71: 86–88, 1978PubMedGoogle Scholar
  129. Ross DA, Gayle GR. Reduction of the renal toxicity of cisdichlorodiammineplatinum (II) by probenecid. Cancer Treatment Reports 63: 781–787, 1979PubMedGoogle Scholar
  130. Rybak LP. Ototoxicity of ethacrynic acid (a persistent clinical problem). Journal of Laryngology and Otology 102: 518–520, 1988PubMedGoogle Scholar
  131. Rybak LP, Whitworth C. Some organic acids attenuate the effects of furosemide on the endocochlear potential. Hearing Research 26: 89–93, 1987PubMedGoogle Scholar
  132. Rybak LP, Whitworth C. Effects of organic acids on the edema of the stria vascularis induced by furosemide. Association for Research in Otolaryngology 11th Midwinter Meeting, Clearwater Beach, Florida, January 31–February 4, 1988. Abstract no. 143, p. 116, 1988Google Scholar
  133. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cis-platinum by rat kidney. Kidney International 25: 753–758, 1984PubMedGoogle Scholar
  134. Salt AN, Melichar I, Thalmann R. Mechanisms of endocochlear potential generation by stria vascularis. Laryngoscope 97: 984–991, 1987PubMedGoogle Scholar
  135. Salvi RI, Kamen BA. Interaction of noise and cisplatinum. Association for Research in Otolaryngology 11th Midwinter Meeting, Clearwater Beach, Florida, January 31–February 4, 1988. Abstract no. 81, p. 68, 1988Google Scholar
  136. Savolainen K, Riihimaki V, Vaheri E, Linnoila M. Effects of xylene and alcohol on vestibular and visual functions in man. Scandinavian Journal of Work Environment and Health 6: 94–103, 1980Google Scholar
  137. Sawyers CL, Moore RD, Lerner SA, et al. A model for predicting nephrotoxicity in patients treated with aminoglycosides. Journal of Infectious Disease 153: 1062–1068, 1986Google Scholar
  138. Schacht J. Isolation of an aminoglycoside receptor from guinea pig inner ear tissues and kidneys. Archives of Otorhinolaryngology 224: 129–134, 1979Google Scholar
  139. Schacht J. Molecular mechanism of drug-induced hearing loss. Hearing Research 22: 297–304, 1986PubMedGoogle Scholar
  140. Schacht J, Lodhi S, Weiner ND. Effects of neomycin on polyphosphoinositides in inner ear tissues and monomolecular films. Advances in Experimental Medical Biology 89: 191–208, 1977Google Scholar
  141. Schaefer SD, Post JD, Close LG, Wright CG. Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 1934–1939, 1985PubMedGoogle Scholar
  142. Schuknecht HF. Ablation therapy in the management of Méniere’s disease. Acta Oto-Laryngologica 132: 1–42, 1957Google Scholar
  143. Schwartz GH, David DS, Riggio RR, et al. Ototoxicity induced by furosemide. New England Journal of Medicine 282: 1413–1414, 1970PubMedGoogle Scholar
  144. Schweitzer VG, Dolan DF, Abrams GE, et al. Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope 96: 948–958, 1986PubMedGoogle Scholar
  145. Schweitzer VG, Hawkins JE, Lilly DJ, et al. Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngology —Head and Neck Surgery 92: 38–49, 1984PubMedGoogle Scholar
  146. Schweitzer VG, Rarey KE, Dolan DF, et al. Ototoxicity of cisplatin vs platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngology —Head and Neck Surgery 94: 458–470, 1986PubMedGoogle Scholar
  147. Schwertz DW, Kreisberg JI, Venkatachalam MA. Gentamicin-induced alterations in pig kidney epithelial (LLC-PK1) cell in culture. Journal of Pharmacology and Experimental Therapeutics 236: 254–262, 1986PubMedGoogle Scholar
  148. Silverstein H, Bernstein JM, Davies DG. Salicylate ototoxicity: a biochemical and electrophysiological study. Annals of Otology, Rhinology and Laryngology 76: 118–128, 1967Google Scholar
  149. Skinner R, Pearson ADJ, Amineddine HA, et al. Ototoxicity of cisplatinum. British Journal of Cancer 58: 261, 1988Google Scholar
  150. Smith CA, Davis H, Deatherage BH, Gessert CF. DC potentials of the membranous labyrinth. American Journal of Physiology 193: 203–206, 1958PubMedGoogle Scholar
  151. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of nephrotoxicity and auditory toxicity of gentamicin and tobramycin. New England Journal of Medicine 302: 1106–1109, 1980PubMedGoogle Scholar
  152. Stupp H, Kupper K, Lagler F, Sous H, Quante M. Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application. Audiology 12: 350–363, 1973PubMedGoogle Scholar
  153. Stypulkowski PH. The mechanism(s) of salicylate (aspirin) induced hearing loss and tinnitus. Association for Research in Otolaryngology 12th Midwinter Meeting, St Petersburg Beach, Florida, February 5–9, 1989. Abstract no. 225, p. 189, 1989Google Scholar
  154. Sullivan M, Rarey K, Conolly R. Ototoxicity of toluene in rats. Neurotoxicology and Teratology 10: 525–530, 1988PubMedGoogle Scholar
  155. Szot RJ, McCormick M, Chung B, et al. Comparative toxicity of netilmicin and tobramycin in dogs. Toxicology and Applied Pharmacology 55: 169–178, 1980PubMedGoogle Scholar
  156. Tachibana M, Anniko M, Schacht J. Effects of perilymphatically perfused gentamicin on microphonic potential, lipid labelling and morphology of cochlear tissues. Acta Oto-Laryngologica 96: 31–38, 1983PubMedGoogle Scholar
  157. Takada A, Bledsoe Jr S, Schacht J. An energy-dependent step in aminoglycoside ototoxicity: prevention of gentamicin ototoxicity during reduced endolymphatic potential. Hearing Research 19: 245–251, 1985PubMedGoogle Scholar
  158. Takada A, Schacht J. Calcium antagonism and reversibility of gentamicin-induced loss of cochlear microphonics in the guinea pig. Hearing Research 8: 179–186, 1982PubMedGoogle Scholar
  159. Takumida M, Wersäll J, Bagger-Sjöbäck D. Initial changes in the sensory hair-cell membrane following aminoglycoside administration in a guinea pig model. Archives of Otorhinolaryngology 246: 26–31, 1989Google Scholar
  160. Tange RA, Conjin EAJG, van Zeijl LPGM. The cortitoxic effects of cis-platinum in the guinea pig. Archives of Otorhinolaryngology 237: 17–26, 1982Google Scholar
  161. Tange RA, Vuzcvski VD. Changes in the stria vascularis of the guinea pig due to cis-platinum. Archives of Otorhinolaryngology 41–47, 1983Google Scholar
  162. Tay LK, Bregman CL, Masters BA, Williams PD. Effects of cisdiammino-dichloroplatinum (II) on rabbit kidney in vivo and on rabbit renal proximal cells in culture. Cancer Research 48: 2538–2543, 1988PubMedGoogle Scholar
  163. Tjernström O, Denneberg T, Harris S, et al. Ototoxicity of netilmicin. Acta Oto-Laryngologica 94: 421–429, 1982PubMedGoogle Scholar
  164. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissues and fluids with other organs. Journal of Clinical Investigation 77: 1492–1500, 1986PubMedGoogle Scholar
  165. Tran Ba Huy P, Manuel C, Meulemans A, et al. Ethacrynic acid facilitates gentamicin entry into endolymph of the rat. Hearing Research 11: 191–202, 1983PubMedGoogle Scholar
  166. Umeki S, Watanabe M, Yagi S, Soejima R. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity. American Journal of Medical Science 295: 6–10, 1988Google Scholar
  167. Vakil N, Abu-Alfa A, Mujais SK. Gentamicin nephrotoxicity in extrahepatic cholestasis: modulation by dietary calcium. Hepatology 9: 519–524, 1989PubMedGoogle Scholar
  168. Vernon J, Brummett RE. Noise trauma in the presence of loop-inhibiting diuretics. Transactions of the American Academy of Ophthalmology and Otolaryngology 84: 407–413, 1977Google Scholar
  169. Verpooten GA, Guiliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clinical Pharmacology and Therapeutics 45: 22–27, 1989PubMedGoogle Scholar
  170. Von Békésy G. DC resting potentials inside the cochlear partition. Journal of the Acoustical Society of America 24: 72–76, 1952Google Scholar
  171. Wagner T, Kreft B, Bohlmann G, Schwieder G. Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. Journal of Cancer Research and Clinical Oncology 114: 497, 1988PubMedGoogle Scholar
  172. Waksman SA. Streptomycin: background, isolation, properties and utilization. Science 118: 259–266, 1953PubMedGoogle Scholar
  173. Wallin JD, Clifton G, Kaplowitz N. The effect of phenobarbital, probenecid and diethyl maleate on the pharmacokinetics and biliary excretion of ethacrynic acid in the rat. Journal of Pharmacology and Experimental Therapeutics 205: 471, 1978PubMedGoogle Scholar
  174. Wang MB, Weiner ND, Takada A, Schacht J. Characterization of aminoglycoside-lipid interactions and development of a refined model for ototoxicity testing. Biochemical Pharmacology 33: 3257–3262, 1984PubMedGoogle Scholar
  175. Ward JM, Grabin ME, Berlin E, Young DM. Prevention of renal failure in rats receiving cis-diamminedichloroplatinum (II) by administration of furosemide. Cancer Research 37: 1238–1240, 1977PubMedGoogle Scholar
  176. Wersäll J. The ototoxic potential of netilmicin compared with amikacin: an animal study in guinea pigs. Scandinavian Journal of Infectious Disease 23 (Suppol.): 104–113, 1980Google Scholar
  177. Wersäll J, Flock Å. Suppression and restoration of the microphonic output from the lateral line organ after local application of streptomycin. Life Science 3: 1151–1155, 1964Google Scholar
  178. West BA, Brummett RE, Hirnes DL. Interaction of kanamycin and ethacrynic acid. Archives of Otolaryngology 98: 32–37, 1973PubMedGoogle Scholar
  179. Williams SE, Zenner HP, Schacht J. Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. Hearing Research 30: 11–18, 1987PubMedGoogle Scholar
  180. Wong NLM, Magil AB, Dirks JH. Effect of magnesium diet in gentamicin-induced acute renal failure in rats. Nephron 51: 84–88, 1989PubMedGoogle Scholar
  181. Wright CG, Schaefer SD. Inner ear histopathology in patients treated with cis-platinum. Laryngoscope 92: 1408–1413, 1982PubMedGoogle Scholar
  182. Yamane H, Nakai Y, Konishi K. Furosemide-induced alteration of drug pathway to cochlea. Acta Oto-Laryngologica (Suppl.) 447: 28–35, 1988Google Scholar
  183. Young JS, Fechter LD. Trimethyltin exposure produces an unusual form of toxic auditory damage in rats. Toxicology and Applied Pharmacology 82: 87–93, 1986PubMedGoogle Scholar
  184. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammine platinum (II) by WR-27-21 without altering its anti-tumor properties. Cancer Treatment Reports 64: 57–64, 1980PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • May Y. Huang
    • 1
  • Jochen Schacht
    • 1
  1. 1.Kresge Hearing Research Institute and Department of OtolaryngologyUniversity of MichiganAnn ArborUSA

Personalised recommendations